OTCMKTS:BIOAF Bioasis Technologies (BIOAF) Stock Price, News & Analysis → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free BIOAF Stock Alerts $0.0040 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.0040▼$0.004050-Day Range$0.0036▼$0.009652-Week Range$0.0015▼$0.0182VolumeN/AAverage Volume20,718 shsMarket Capitalization$317,640.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartShort InterestStock AnalysisChartShort Interest Get Bioasis Technologies alerts: Email Address Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. About Bioasis Technologies Stock (OTCMKTS:BIOAF)Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.Read More BIOAF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIOAF Stock News HeadlinesMarch 21, 2024 | finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - BTIJanuary 9, 2024 | morningstar.comBioasis Technologies Inc 107April 27, 2024 | Tranzact (Ad)What is Medicare Supplement Insurance?Original Medicare helps covers a lot of hospital and medical services, but it still leaves some out- of- pocket medical costs to recipients. Make sure your family’s nest egg is protected from unpredictable medical expenses. Consider applying for a Medicare Supplement Insurance Plan that travels with you. August 1, 2023 | investing.combiOasis Technologies Inc (BTI) Earnings Dates & ReportsJune 27, 2023 | benzinga.comShort Volatility Alert: Bioasis Tech IncJune 22, 2023 | chron.comNew Haven biotech company suspending operations after failed mergerJune 21, 2023 | finanznachrichten.deBioasis Technologies Inc.: Bioasis Provides Corporate Update and Announces Suspension of OperationsMarch 23, 2023 | finance.yahoo.comBioasis Provides Update on Business OperationsApril 27, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.January 19, 2023 | finance.yahoo.comBioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2022December 16, 2022 | chron.comNew Haven-based biotech company signs $5.42 million agreement to merge with British companyDecember 13, 2022 | marketwatch.comMidatech Pharma Shares Fall on Bioasis Technologies Buy, Plan to Cancel AIM ListingDecember 13, 2022 | finance.yahoo.com/C O R R E C T I O N -- Investment Industry Regulatory Organization of Canada (IIROC) - ResumptionsOctober 29, 2022 | finance.yahoo.comBioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2022August 8, 2022 | finance.yahoo.comBioasis Technologies Inc. Announces Stock Option GrantsJune 16, 2022 | finance.yahoo.comBioasis Acquires Phase 2 Ready Rare Orphan EGF AssetsApril 26, 2022 | finance.yahoo.comBIOAF: Collaboration Arrangement with JanssenApril 11, 2022 | seekingalpha.comBioasis enters into research collaboration with Janssen for its xB3 platformApril 11, 2022 | finance.yahoo.comBioasis Enters Into Research Collaboration With JanssenJanuary 31, 2022 | finance.yahoo.comBIOAF: Third Quarter ResultsJanuary 20, 2022 | sfgate.comBiOasis: Fiscal Q3 Earnings SnapshotJanuary 20, 2022 | finance.yahoo.comBioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending November 30, 2021January 16, 2022 | nasdaq.comBioasis Technologies Inc (BIOAF)November 3, 2021 | finance.yahoo.comBIOAF: Second Quarter UpdateOctober 28, 2021 | finance.yahoo.comBioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2021August 18, 2021 | apnews.comBioasis Technologies Inc. Announces the Appointment of Shadow Lake Group as Business ...August 18, 2021 | financialpost.comBioasis Technologies Inc. Announces the Appointment of Shadow Lake Group as Business Development AdvisorSee More Headlines Receive BIOAF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bioasis Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/27/2021Today4/27/2024Fiscal Year End2/28/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drugs, proprietaries, & sundries Sub-IndustryN/A Current SymbolOTCMKTS:BIOAF CUSIPN/A CIKN/A Webwww.bioasis.us Phone(203) 533-7082FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$30,000.00 Price / Sales10.59 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares79,410,000Free FloatN/AMarket Cap$317,640.00 OptionableNot Optionable Beta0.86 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Deborah Ann Rathjen B.Sc. (Hons.) (Age 66)FTSE, M.A.I.C.D., Ph.D., Q.C., Executive Chairman, CEO & President Comp: $153.73kMr. David P. Jenkins (Age 62)Chief Financial Officer Comp: $92.23kMr. Graeme DickDirector of Investor RelationsMr. Aaron EltonDirector of MarketingDr. Mei Mei TianVP & Head of External ResearchKey CompetitorsChina SXT PharmaceuticalsNASDAQ:SXTCAvivagenOTCMKTS:VIVXFSpectraScienceOTCMKTS:SCIEHempstractOTCMKTS:HPSTH-CYTEOTCMKTS:HCYTDView All Competitors BIOAF Stock Analysis - Frequently Asked Questions How have BIOAF shares performed in 2024? Bioasis Technologies' stock was trading at $0.0047 at the beginning of 2024. Since then, BIOAF shares have decreased by 14.9% and is now trading at $0.0040. View the best growth stocks for 2024 here. How were Bioasis Technologies' earnings last quarter? Bioasis Technologies Inc. (OTCMKTS:BIOAF) released its quarterly earnings results on Wednesday, October, 27th. The company reported ($0.01) earnings per share for the quarter, hitting the consensus estimate of ($0.01). How do I buy shares of Bioasis Technologies? Shares of BIOAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:BIOAF) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioasis Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
